請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37954完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林亮音(Liang-In Lin) | |
| dc.contributor.author | Cheng-Yeh Lee | en |
| dc.contributor.author | 李承曄 | zh_TW |
| dc.date.accessioned | 2021-06-13T15:53:11Z | - |
| dc.date.available | 2008-08-13 | |
| dc.date.copyright | 2008-08-13 | |
| dc.date.issued | 2008 | |
| dc.date.submitted | 2008-06-23 | |
| dc.identifier.citation | 1 Estey,E. and Dohner,H. Acute myeloid leukaemia, Lancet, 368: 1894-1907, 2006.
2 Jemal,A., Siegel,R., Ward,E., Hao,Y.P., Xu,J.Q., Murray,T. and Thun,M.J. Cancer statistics, 2008, Ca-A Cancer Journal for Clinicians, 58: 71-96, 2008. 3 中華民國公共衛生學會癌症登記小組 Cancer Registration System 中華民國94年癌症登記報告 Cancer Registry Annual Report, 2005, Taiwan, http://crs.cph.ntu.edu.tw/crs_c/index.htm, 2008. 4 Deschler,B. and Lubbert,M. Acute myeloid leukemia: Epidemiology and etiology, Cancer, 107: 2099-2107, 2006. 5 Bennett,J.M., Catovsky,D., Daniel,M.T., Flandrin,G., Galton,D.A.G., Gralnick,H.R. and Sultan,C. Proposed Revised Criteria for the Classification of Acute Myeloid-Leukemia - A Report of the French-American-British Cooperative Group, Annals of Internal Medicine, 103: 620-625, 1985. 6 Vardiman,J.W., Harris,N.L. and Brunning,R.D. The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100: 2292-2302, 2002. 7 Mrozek,K. and Bloomfield,C.D. Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia, Hematology, 2006: 169-177, 2006. 8 Baldus,C.D., Mrozek,K., Marcucci,G. and Bloomfield,C.D. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review, British Journal of Haematology, 137: 387-400, 2007. 9 Barragan,E., Cervera,J., Bolufer,P., Ballester,S., Martin,G., Fernandez,P., Collado,R., Sayas,M.J. and Sanz,M.A. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia, Haematologica, 89: 926-933, 2004. 10 Del Poeta,G., Venditti,A., Del Principe,M.I., Maurillo,L., Buccisano,F., Tamburini,A., Cox,M.C., Franchi,A., Bruno,A., Mazzone,C., Panetta,P., Suppo,G., Masi,M. and Amadori,S. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML), Blood, 101: 2125-2131, 2003. 11 Loges,S., Heil,G., Bruweleit,M., Schoder,V., Butzal,M., Fischer,U., Gehling,U.M., Schuch,G., Hossfeld,D.K. and Fiedler,W. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: Expression of angiopoietin-2 represents an independent prognostic factor for overall survival, J Clin Oncol, 23: 1109-1117, 2005. 12 Bergmann,O.J., Johansen,J.S., Klausen,T.W., Mylin,A.K., Kristensen,J.S., Kjeldsen,E. and Johnsen,H.E. High Serum Concentration of YKL-40 Is Associated with Short Survival in Patients with Acute Myeloid Leukemia, Clin Cancer Res, 11: 8644-8652, 2005. 13 Aref,S., Osman,E., Mansy,S., Omer,N., Azmy,E., Goda,T. and EI-Sherbiny,M. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients, Hematological Oncology, 25: 121-126, 2007. 14 Aguayo,A., Kantarjian,H.M., Estey,E.H., Giles,F.J., Verstovsek,S., Manshouri,T., Gidel,C., O'Brien,S., Keating,M.J. and Albitar,M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes, Cancer, 95: 1923-1930, 2002. 15 Lin,L.I., Lin,D.T., Chang,C.J., Lee,C.Y., Tang,J.L. and Tien,H.F. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia, British Journal of Haematology, 117: 835-841, 2002. 16 Carmeliet,P. and Jain,R.K. Angiogenesis in cancer and other diseases, Nature, 407: 249-257, 2000. 17 Polverini,P.J. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities, J Dent Educ., 66: 962-975, 2002. 18 De Raeve,H., Van Marck,E., Van Camp,B. and Vanderkerken,K. Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies, Histology and Histopathology, 19: 935-950, 2004. 19 Dilly,S.A. and Jagger,C.J. Bone-Marrow Stromal Cell Changes in Hematological Malignancies, Journal of Clinical Pathology, 43: 942-946, 1990. 20 Hussong,J.W., Rodgers,G.M. and Shami,P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia, Blood, 95: 309-313, 2000. 21 Padro,T., Ruiz,S., Bieker,R., Burger,H., Steins,M., Kienast,J., Buchner,T., Berdel,W.E. and Mesters,R.M. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia, Blood, 95: 2637-2644, 2000. 22 Aguayo,A., Kantarjian,H., Manshouri,T., Gidel,C., Estey,E., Thomas,D., Koller,C., Estrov,Z., O'Brien,S., Keating,M., Freireich,E. and Albitar,M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes, Blood, 96: 2240-2245, 2000. 23 Podar,K. and Anderson,K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications, Blood, 105: 1383-1395, 2005. 24 Roy,H., Bhardwaj,S. and Yla-Herttuala,S. Biology of vascular endothelial growth factors, Febs Letters, 580: 2879-2887, 2006. 25 Ferrara,N., Gerber,H.P. and LeCouter,J. The biology of VEGF and its receptors, Nature Medicine, 9: 669-676, 2003. 26 Autiero,M., Luttun,A., Tjwa,M. and Carmeliet,P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders, Journal of Thrombosis and Haemostasis, 1: 1356-1370, 2003. 27 Oliver,G. and Alitalo,K. The lymphatic vasculature: Recent progress and paradigms, Annual Review of Cell and Developmental Biology, 21: 457-483, 2005. 28 Achen,M.G., Mann,G.B. and Stacker,S.A. Targeting lymphangiogenesis to prevent tumour metastasis, British Journal of Cancer, 94: 1355-1360, 2006. 29 Ward,N.L. and Dumont,D.J. The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development, Seminars in Cell & Developmental Biology, 13: 19-27, 2002. 30 Thurston,G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis, Cell and Tissue Research, 314: 61-68, 2003. 31 Jones,P.F. Not just angiogenesis - wider roles for the angiopoietins, Journal of Pathology, 201: 515-527, 2003. 32 Shim,W.S.N., Ho,I.A.W. and Wong,P.E.H. Angiopoietin: A TIE(d) balance in tumor angiogenesis, Molecular Cancer Research, 5: 655-665, 2007. 33 Tait,C.R. and Jones,P.F. Angiopoietins in tumours: the angiogenic switch, Journal of Pathology, 204: 1-10, 2004. 34 Reusch,P., Barleon,B., Weindel,K., Martiny-Baron,G., Godde,A., Siemeister,G. and Marme,D. Identification of a soluble form of th angiopoietin receptor TIE-2 released from endothelial cell and present in human blood, Angiogenesis, 4: 123-131, 2001. 35 Kuter,D.J., Bain,B., Mufti,G., Bagg,A. and Hasserjian,R.P. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres, British Journal of Haematology, 139: 351-362, 2007. 36 Wilson,A. and Trumpp,A. Bone-marrow haematopoietic-stem-cell niches, Nature Reviews Immunology, 6: 93-106, 2006. 37 Blank,U., Karlsson,G. and Karlsson,S. Signaling pathways governing stem-cell fate, Blood, 111: 492-503, 2008. 38 Yin,T. and Li,L.H. The stem cell niches in bone, Journal of Clinical Investigation, 116: 1195-1201, 2006. 39 Suda,T., Arai,F. and Hirao,A. Hematopoietic stem cells and their niche, Trends in Immunology, 26: 426-433, 2005. 40 Moore,K.A. and Lemischka,I.R. Stem cells and their niches, Science, 311: 1880-1885, 2006. 41 Mitsiadis,T.A., Omella,B., Rochat,A., Barrandon,Y. and Bari,C. Stem cell niches in mammals, Experimental Cell Research, 313: 3377-3385, 2007. 42 Arai,F., Hirao,A., Ohmura,M., Sato,H., Matsuoka,S., Takubo,K., Ito,K., Koh,G.Y. and Suda,T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche, Cell, 118: 149-161, 2004. 43 Arai,F., Hirao,A. and Suda,T. Regulation of hematopoietic stem cells by the niche, Trends in Cardiovascular Medicine, 15: 75-79, 2005. 44 Colmone,A. and Sipkins,D.A. Beyond angiogenesis: the role of endothelium in the bone marrow vascular niche, Translational Research, 151: 1-9, 2008. 45 Wai,P.Y. and Kuo,P.C. The role of osteopontin in tumor metastasis, Journal of Surgical Research, 121: 228-241, 2004. 46 Haylock,D.N. and Nilsson,S.K. Osteopontin: a bridge between bone and blood, British Journal of Haematology, 134: 467-474, 2006. 47 Rangaswami,H., Bulbule,A. and Kundu,G.C. Osteopontin: role in cell signaling and cancer progression, Trends in Cell Biology, 16: 79-87, 2006. 48 Rittling,S.R. and Chambers,A.F. Role of osteopontin in tumour progression, British Journal of Cancer, 90: 1877-1881, 2004. 49 Litwin,C., Leong,K.G., Zapf,R., Sutherland,H., Naiman,S.C. and Karsan,A. Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia, American Journal of Hematology, 70: 22-30, 2002. 50 Liu,P., Li,J.Y., Han,Z.C., Lu,H., Wang,Y., Xu,B. and Peng,Z. Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia, Leukemia & Lymphoma, 46: 1761-1764, 2005. 51 Nowicki,M., Ostalska-Nowicka,D., Kaczmarek,E., Miskowiak,B. and Witt,M. Vascular endothelial growth factor C - a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach, Histopathology, 49: 170-177, 2006. 52 Moehler,T.M., Ho,A.D., Goldschmidt,H. and Barlogie,B. Angiogenesis in hematologic malignancies, Critical Reviews in Oncology Hematology, 45: 227-244, 2003. 53 Tordjman,R., Ortega,N., Coulombel,L., Plouet,J., Romeo,P.H. and Lemarchandel,V. Neuropilin-1 Is Expressed on Bone Marrow Stromal Cells: A Novel Interaction With Hematopoietic Cells?, Blood, 94: 2301-2309, 1999. 54 Oostendorp,R.A.J. and Dormer,P. VLA-4-mediated interactions between normal human hematopoietic progenitors and stromal cells, Leukemia & Lymphoma, 24: 423-435, 1997. 55 Ogawa,M., LaRue,A.C. and Drake,C.J. Hematopoietic origin of fibroblasts/myofibroblasts: its pathophysiologic implications, Blood, 108: 2893-2896, 2006. 56 Donckier,J.E., Michel,L., Delos,M., Havaux,X. and Van Beneden,R. Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma, Clinical Endocrinology, 64: 703-710, 2006. 57 Tang,R.F., Wang,S.X., Peng,L., Wang,S.X., Zhang,M., Li,Z.F., Zhang,Z.M., Xiao,Y. and Zhang,F.R. Expression of vascular endothelial growth factors A and C in human pancreatic cancer, World Journal of Gastroenterology, 12: 280-286, 2006. 58 Caine,G.J., Blann,A.D., Stonelake,P.S., Ryan,P. and Lip,G.Y.H. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1, European Journal of Clinical Investigation, 33: 883-890, 2003. 59 Krauth,M.T., Simonitsch,I., Aichberger,K.J., Mayerhofer,M., Sperr,W.R., Sillaber,C., Schneeweiss,B., Mann,G., Gadner,H. and Valent,P. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease, American Journal of Clinical Pathology, 121: 473-481, 2004. 60 Wimazal,F., Krauth,M.T., Vales,A., Bohm,A., Agis,H., Sonneck,K., Aichberger,K.J., Mayerhofer,M., Simonitsch-Klupp,I., Mullauer,L., Sperr,W.R. and Valent,P. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category, Leukemia & Lymphoma, 47: 451-460, 2006. 61 Keith,T., Araki,Y., Ohyagi,M., Hasegawa,M., Yamamoto,K., Kurata,M., Nakagawa,Y., Suzuki,K. and Kitagawa,M. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia, British Journal of Haematology, 137: 206-215, 2007. 62 Hou,H.A., Chou,W.C., Lin,L.I., Tang,J.L., Tseng,M.H., Huang,C.F., Yao,M., Chen,C.Y., Tsay,W. and Tien,H.F. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia, Leukemia Research, 32: 904-912, 2008. 63 Ghannadan,M., Wimazal,F., Simonitsch,I., Sperr,W.R., Mayerhofer,M., Sillaber,C., Hauswirth,A.W., Gadner,H., Chott,A., Horny,H.P., Lechner,K. and Valent,P. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia - Correlation between VEGF expression and the FAB category, American Journal of Clinical Pathology, 119: 663-671, 2003. 64 Dias,S., Choy,M., Alitalo,K. and Rafii,S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy, Blood, 99: 2179-2184, 2002. 65 Tsurusaki,T., Kanda,S., Sakai,H., Kanetake,H., Saito,Y., Alitalo,K. and Koji,T. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis, British Journal of Cancer, 80: 309-313, 1999. 66 Kitadai,Y., Amioka,T., Haruma,K., Tanaka,S., Yoshihara,M., Sumii,K., Matsutani,N., Yasui,W. and Chayama,K. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas, International Journal of Cancer, 93: 662-666, 2001. 67 Fielder,W., Graeven,U., Ergun,S., Verago,S., Kilic,N., Stockschlader,M. and Hossfeld,D.K. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia, Leukemia, 11: 1234-1237, 1997. 68 Niki,T., Iba,S., Tokunou,M., Yamada,T., Matsuno,Y. and Hirohashi,S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma, Clin Cancer Res, 6: 2431-2439, 2000. 69 Onogawa,S., Kitadai,Y., Tanaka,S., Kuwai,T., Kimura,S. and Chayama,K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma, Cancer Science, 95: 32-39, 2004. 70 Muller,A., Lange,K., Gaiser,T., Hofmann,M., Bartels,H., Feller,A.C. and Merz,H. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia, Leukemia Research, 26: 163-168, 2002. 71 Schliemann,C., Bieker,R., Padro,T., Kessler,T., Hintelmann,H., Buchner,T., Berdel,W.E. and Mesters,R.M. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia, Haematologica-the Hematology Journal, 91: 1203-1211, 2006. 72 Hatfield,K.J., Hovland,R., Oyan,A.M., Kalland,K.H., Ryningen,A., Gjertsen,B.T. and Bruserud,O. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels, Leukemia, 22: 287-293, 2008. 73 Faderl,S., Do,K.A., Johnson,M.M., Keating,M., O'Brien,S., Jilani,I., Ferrajoli,A., Ravandi-Kashani,F., Aguilar,C., Dey,A., Thomas,D.A., Giles,F.J., Kantarjian,H.M. and Albitar,M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia, Blood, 106: 4303-4307, 2005. 74 Verstovsek,S., Kantarjian,H., Manshouri,T., Cortes,J., Giles,F.J., Rogers,A. and Albitar,M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia, Blood, 99: 2265-2267, 2002. 75 Juttner,S., Wissmann,C., Jons,T., Vieth,M., Hertel,J., Gretschel,S., Schlag,P.M., Kemmner,W. and Hocker,M. Vascular Endothelial Growth Factor-D and Its Receptor VEGFR-3: Two Novel Independent Prognostic Markers in Gastric Adenocarcinoma, J Clin Oncol, 24: 228-240, 2006. 76 Schliemann,C., Bieker,R., Thoennissen,N., Gerss,J., Liersch,R., Kessler,T., Buchner,T., Berdel,W.E. and Mesters,R.M. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia, Leukemia, 21: 1901-1906, 2007. 77 Zhang,J., Takahashi,K., Takahashi,F., Shimizu,K., Ohshita,F., Kameda,Y., Maeda,K., Nishio,K. and Fukuchi,Y. Differential osteopontin expression in lung cancer, Cancer Letters, 171: 215-222, 2001. 78 Kim,J., Ki,S.S., Lee,S.D., Han,C.J., Kim,Y.C., Park,S.H., Cho,S.Y., Hong,Y.J., Park,H.Y., Lee,M., Jung,H.H., Lee,K.H. and Jeong,S.H. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma, American Journal of Gastroenterology, 101: 2051-2059, 2006. 79 Donati,V., Boldrini,L., Dell'Omodarme,M., Prati,M.C., Faviana,P., Camacci,T., Lucchi,M., Mussi,A., Santoro,M., Basolo,F. and Fontanini,G. Osteopontin expression and prognostic significance in non-small cell lung cancer, Clin Cancer Res, 11: 6459-6465, 2005. 80 Kita,Y., Natsugoe,S., Okumura,H., Matsumoto,M., Uchikado,Y., Setoyama,T., Owaki,T., Ishigami,S. and Aikou,T. Expression of Osteopontin in oesophageal squamous cell carcinoma, British Journal of Cancer, 95: 634-638, 2006. 81 Coppola,D., Szabo,M., Boulware,D., Muraca,P., Alsarraj,M., Chambers,A.F. and Yeatman,T.J. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies, Clin Cancer Res, 10: 184-190, 2004. 82 Fedarko,N.S., Jain,A., Karadag,A., Van Eman,M.R. and Fisher,L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer, Clin Cancer Res, 7: 4060-4066, 2001. 83 Hotte,S.J., Winquist,E.W., Stitt,L., Wilson,S.M. and Chambers,A.F. Plasma osteopontin - Associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma, Cancer, 95: 506-512, 2002. 84 Nakae,M., Iwamoto,I., Fujino,T., Maehata,Y., Togami,S., Yoshinaga,M. and Douchi,T. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer, Journal of Obstetrics and Gynaecology Research, 32: 309-314, 2006. 85 Singhal,H., Bautista,D.S., Tonkin,K.S., O'Malley,F.P., Tuck,A.B., Chambers,A.F. and Harris,J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival, Clin Cancer Res, 3: 605-611, 1997. 86 Flamant,S., Kortulewski,T., Dugray,A., Bonnet,M.L., Guillier,M., Guilhot,F., Bourhis,J.H., Vainchenker,W., Roux,D.T.L. and Turhan,A.G. Osteopontin is upregulated by BCR-ABL, Biochemical and Biophysical Research Communications, 333: 1378-1384, 2005. 87 Standal,T., Hjorth-Hansen,H., Rasmussen,T., Dahl,I.M.S., Lenhoff,S., Brenne,A.T., Seidel,C., Baykov,V., Waage,A., Borset,M., Sundan,A. and Hjertner,O. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma, Haematologica, 89: 174-182, 2004. 88 Saeki,Y., Mima,T., Ishii,T., Ogata,A., Kobayashi,H., Ohshima,S., Ishida,T., Tabunoki,Y., Kitayama,H., Mizuki,M., Katada,Y., Asaoku,H., Kitano,M., Nishimoto,N., Yoshizaki,K., Maeda,M., Kon,S., Kinoshita,N., Uede,T. and Kawase,I. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications, British Journal of Haematology, 123: 263-270, 2003. 89 Nilsson,S.K., Johnston,H.M., Whitty,G.A., Williams,B., Webb,R.J., Denhardt,D.T., Bertoncello,I., Bendall,L.J., Simmons,P.J. and Haylock,D.N. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells, Blood, 106: 1232-1239, 2005. 90 Stier,S., Ko,Y., Forkert,F., Lutz,C., Neuhaus,T., Grunewald,E., Cheng,T., Dombkowski,D., Calvi,L.M., Rittling,S.R. and Scadden,D.T. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size, Journal of Experimental Medicine, 201: 1781-1791, 2005. 91 Bramwell,V.H.C., Doig,G.S., Tuck,A.B., Wilson,S.M., Tonkin,K.S., Tomiak,A., Perera,F., Vandenberg,T.A. and Chambers,A.F. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer, Clin Cancer Res, 12: 3337-3343, 2006. 92 Le,Q.T., Sutphin,P.D., Raychaudhuri,S., Yu,S.C.T., Terris,D.J., Lin,H.S., Lum,B., Pinto,H.A., Koong,A.C. and Giaccia,A.J. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas, Clin Cancer Res, 9: 59-67, 2003. 93 Matusan,K., Dordevic,G., Stipic,D., Mozetic,V. and Lucin,K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma, Journal of Surgical Oncology, 94: 325-331, 2006. 94 Shijubo,N., Uede,T., Kon,S., Maeda,M., Segawa,T., Imada,A., Hirasawa,M. and Abe,S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma, American Journal of Respiratory and Critical Care Medicine, 160: 1269-1273, 1999. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37954 | - |
| dc.description.abstract | 急性骨髓性白血病（AML）是一種造血細胞發生變異導致的疾病。由於AML在血液腫瘤中具有高發生率及低存活率，發展生物指標幫助臨床診斷及預後評估，顯得相當重要。本研究從血管新生作用及幹細胞調控機制兩方向，希望尋找合適之AML生物指標。共收集52名剛發病的AML患者，與20名正常骨髓捐贈者，以酵素免疫分析法測量骨髓血漿中的蛋白濃度。
骨髓中的血管新生作用，被認為和AML的致病機轉有關。本研究討論的血管新生因子，主要來自和血管新生最有關的vascular endothelial growth factor（VEGF）家族和angiopoietin（Ang）家族。共有VEGF-A、VEGF/PlGF、VEGF-C、VEGF-D、Ang-1、Ang-2、Tie-2七種。和正常對照相比，骨髓血漿中的VEGF/PlGF、Ang-2、Tie-2的濃度在AML病患顯著升高，VEGF-C與Ang-1濃度則顯著降低。以31名經過治療的病患進行存活分析，發現Ang-2和Tie-2濃度低、VEGF/PlGF和VEGF-D濃度高的AML病患，有較佳的預後。更進一步以上述四項因子，建立血管新生係數（angio-index），計算公式為(Ang-2×Tie-2)/(VEGF/PlGF×VEGF-D)。使用存活及迴歸分析都觀察到，血管新生係數較高的病患，有較差的預後。 在骨髓利基（bone marrow niche）中，造骨蛋白osteopontin（OPN）扮演維持造血幹細胞靜止狀態的角色，同時也可負向調控其生長及活性。本研究發現，OPN的濃度在AML病患較正常對照顯著增加。在31名進行存活分析的病患中，低OPN濃度者有較好的一年存活率。多變項迴歸分析則顯示，不論在一年或五年的追蹤，高OPN濃度之病患都有較差的預後。 綜合以上結果，本研究為AML的診斷及預後評估，提供了相當好的指標。對於今後的生物指標發展，也提出新的方向。 | zh_TW |
| dc.description.abstract | Acute myeloid leukemia (AML) is a heterogenous clonal disorder of hematopoietic cells. Because AML has high incidence rate and low survival probability among hematopoietic malignancies, it is important to develop biomarkers for clinical diagnosis and prognosis prediction. In the present study, AML biomarkers were estimated from two directions, angiogenesis and stem cell regulation. Bone marrow (BM) plasma from 52 AML patients before chemotherapy and 20 healthy controls were included, and protein concentrations were detected by ELISA.
Angiogenesis in BM was thought to correlate with pathogenesis of AML. Vascular endothelial growth factor (VEGF) and angiopoietin (Ang) are the two families involved in the angiogenesis. Seven angiogenic factors were investigated in this study: VEGF-A, VEGF/PlGF, VEGF-C, VEGF-D, Ang-1, Ang-2, and Tie-2. Comparing to normal controls, the marrow levels of VEGF/PlGF, Ang-2, and Tie-2 were significantly higher, and those of VEGF-C and Ang-1 were significantly lower in the AML patients. Thirty-one patients were further subjected to survival analysis. Patients with lower Tie-2 and Ang-2 levels displayed a survival advantage, same as patients with higher VEGF/PlGF and VEGF-D levels. An angio-index [(Ang-2×Tie-2)/(VEGF/PlGF×VEGF-D)] was established. Both survival analysis and Cox regression models revealed that patients with higher angio-index values displayed poor prognosis Osteopontin (OPN) appears to maintain hematopoietic stem cells quiescence in BM niche and to negatively regulate their proliferation and activity. The marrow OPN levels were significantly higher in AML patients than those in healthy controls. Of the 31 patients subjected to survival analysis, those with lower OPN displayed a longer survival time in one-year analysis. Multivariate Cox regression models revealed patients with higher OPN level displayed poor prognosis in both one-year and five-year analysis. As a summary, this study provided good biomarkers for AML diagnosis and prognosis. It also showed new directions for AML biomarker discovery. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T15:53:11Z (GMT). No. of bitstreams: 1 ntu-97-D92424002-1.pdf: 2318616 bytes, checksum: f12ec685fa41af59be9193b883d9d161 (MD5) Previous issue date: 2008 | en |
| dc.description.tableofcontents | 口試委員會審定書
目錄 i 中文摘要 iii 英文摘要（Abstract） v 圖目錄 vii 表目錄 xi 縮寫表 xiii 第一章 前言 1 1.1急性骨髓性白血病（AML） 1 1.2 AML之診斷及治療 2 1.3 AML之預後指標 6 1.4血管新生作用 8 1.5造血作用與骨髓環境 12 第二章 研究目的 19 第三章 研究方法 21 3.1研究對象之選取 21 3.2檢體之處理與保存 22 3.3酵素免疫分析法（ELISA） 22 3.4統計分析 28 第四章 結果 31 4.1血管新生因子作為AML生物指標之評估 31 4.2造骨蛋白OPN作為AML生物指標之評估 132 第五章 討論 159 5.1使用骨髓血漿進行研究之優點 159 5.2血管新生相關因子作為生物指標之評估 159 5.3造骨蛋白OPN作為生物指標之評估 165 5.4各種相關性比較之探討 168 5.5血管新生相關因子與OPN作為追蹤指標之探討 169 5.6本研究對AML診斷及預後的幫助 170 參考資料 171 | |
| dc.language.iso | zh-TW | |
| dc.title | 急性骨髓性白血病相關生物指標之探索 | zh_TW |
| dc.title | Distinct Biomarker Discovery for Patients with AML | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 96-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 陳建仁,田蕙芬,高照村,黃慶三,何元順,呂健惠 | |
| dc.subject.keyword | 急性骨髓性白血病,生物指標,骨髓,VEGF家族,Ang家族,造骨蛋白osteopontin, | zh_TW |
| dc.subject.keyword | AML,biomarker,bone marrow,VEGF family,Ang family,osteopontin, | en |
| dc.relation.page | 183 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2008-06-24 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
| 顯示於系所單位： | 醫學檢驗暨生物技術學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-97-1.pdf 目前未授權公開取用 | 2.26 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。